State-of-the-art surgical treatment of IPMNs

Roberto Salvia1 · Anna Burelli1 · Giampaolo Perri1 · Giovanni Marchegiani1,2

Received: 1 October 2021 / Accepted: 5 October 2021 / Published online: 4 November 2021
© The Author(s) 2021

Abstract

Background A “pandemic” of incidentally discovered pancreatic cyst neoplasms (PCNs) is ongoing. Among PCNs, intraductal papillary mucinous cystic neoplasms (IPMNs) are the most common and with their complex biology could represent a precursor lesion of pancreatic cancer. Although multiple guidelines exist to guide their treatment, there are still many “gray areas” on indications for surgery for IPMNs.

Methods The current indications for surgery of IPMNs were reappraised, considering potential discrepancies between available evidence and guidelines policies. The practice at a high-volume center for the diagnosis and treatment of PCN was presented and discussed.

Results Most IPMNs do not and will never require surgery, as they won’t progress to malignancy. The current literature is solid in identifying high-grade dysplasia (HGD) as the right and timely target for IPMN resection, but how to precisely assess its presence remains controversial and guidelines lack of accuracy in this regard. Multiple tumorigenic pathways of progression of IPMNs exist, and their knowledge will likely lead to more accurate tests for malignancy prediction in the future.

Conclusions The surgical management of IPMNs still is a matter of debate. Indication for resection should be considered only in highly selected cases with the ideal target of HGD. Clinicians should critically interpret the guidelines’ indications, refer to a multidisciplinary team discussion, and always consider the outcome of an adequate counselling with the patient.

Keyword Intraductal papillary mucinous neoplasms · IPMN · Pancreatic ductal adenocarcinoma · Pancreatic cystic neoplasms · Pancreatic surgery

Overview

In the context of a modern “pandemic” of incidentally discovered pancreatic cyst neoplasms (PCNs) [1], intraductal papillary mucinous cystic neoplasms (IPMNs) are attracting increasing interest among the medical community, as they represent an entity so common and yet so difficult to frame inside a unique, straightforward clinical approach. Given that IPMNs represent a precursor lesion of pancreatic cancer [2], their treatment was originally based on a blind, aggressive surgical approach due to lack of reliable data on their biology and a high presumed risk of malignancy.

However, surveillance for selected cases has gained more and more favor thanks to the progressive availability of new evidence from large observational studies, highlighting how most cases can be safely surveilled over time due to a low risk of malignant progression [3–6].

Three main guidelines on the management of PCNs exist: (1) the guidelines of the International Association of Pancreatoflology (IAP), published in 2006 and updated in 2012 and 2016; (2) the European evidence-based guidelines published in 2013 and updated in 2017; and (3) the guidelines of the American Gastroenterological Association (AGA) published in 2015 [7–9]. These guidelines tend to be consistent regarding the main indications for surgery, while they diverge on the indications for surveillance and surveillance discontinuation. Despite their undoubtful clinical utility, guidelines are obviously mainly based on expert opinions. Recommendations are based on scientific evidence provided by few observational studies and mostly surgical series, which still probably overestimate the risk of developing a malignant disease [7–9]. This surgical bias explains why current guidelines are characterized...
by high sensitivity and low specificity and consequently burdened by high rate of surgical overtreatment. Large observational series were recently published aiming to describe the natural history of IPMNs, but lack of pathological confirmation was inevitably associated with risk of misdiagnosis and of underestimating malignancy [3, 5]. As a matter of fact, forty years after their identification, the natural history of IPMNs remains substantially unraveled. Therefore, a standardized evidence-based clinical management is lacking.

The purpose of the current article is to critically review the surgical treatment of IPMNs, focusing on the indications for surgery and on the various existing controversies between guidelines, evidence, and clinical practice.

Epidemiology and biology of IPMNs

In an era characterized by an extensive use of cross-sectional imaging, a recent meta-analysis estimated a pool prevalence of incidentally discovered PCNs of around 8%, with a 4.7% of cysts “likely to have mucinous nature” [1]. Among pancreatic cysts, IPMNs have a prevalence ranging from 20 to 80% and a potential to progress to cancer following the adenoma-to-carcinoma sequence [10]. Their prevalence and the risk of malignant progression increase with age, with no significant difference between genders and pancreatic location [11]. Two classifications can be applied to IPMNs: morphological and histological. The first identifies main duct IPMNs (MD-IPMNs), branch duct IPMNs, and mixed type IPMNs (MT-IPMNs). Surgical series report a higher rate of malignancy in case of MD- and MT-IPMN (60–92%) compared to BD-IPMNs (6–46%) [12, 13]. Concerning histology, IPMNs are graded as low-grade dysplasia (LGD) or high-grade dysplasia (HGD), based on the architectural and cytologic atypia of their lining epithelium, and they are also subtyped according to the differentiation of this epithelium, as intestinal, gastric, pancreatobiliary, and oncocytic. Also, invasive cancer (IC) arising from IPMNs are subtyped according to their cytological characteristics as tubular, colloid, and oncocytic [14, 15].

The morphological classification of IPMN is relevant in the preoperative setting to assess the risk of malignant progression and, subsequently, to select the most appropriate management. However, the treatment after resection is guided by the presence or absence of an invasive component regardless of morphology [14–16].

Diagnosis

Clinical presentation and symptoms

Once overtaking the bias of surgical series, most IPMNs are asymptomatic [1, 17]. Among symptomatic patients, the majority complaints about aspecific symptoms as diffuse abdominal pain, dyspepsia, and bloating that, probably, do not even correlate with the presence of IPMN. Only very few signs and symptoms can be directly related to the presence of IPMNs, namely, obstructive jaundice, recurrent acute pancreatitis, new-onset or worsening diabetes mellitus, and steatorrhea due to endocrine or exocrine insufficiency. Yet, only jaundice was found to be an independent predictor of HGD or IC [18].

Cross-sectional imaging and endoscopic ultrasound

At diagnosis, it is crucial to distinguish a presumed IPMN from other PCNs and to correctly assess specific radiological features. Computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced endoscopic ultrasound (CE-EUS) are the most widespread diagnostic tools. MRI with magnetic resonance cholangiopancreatography (MRCP) has shown superior to CT in identifying specific type of PCNs, communication with the pancreatic duct system, mural nodules, and multifocal PCNs [19]. However, the accuracy of radiological imaging in identifying specific PCNs subtypes remains low [20], ranging from 39 to 44.7% for CT and from 39.5 to 50% for MRI [21]. Therefore, when features suspicious for degeneration appear, a combined approach with CE-EUS may be required. Clinical guidelines are not unanimous with regard to indications to perform CE-EUS whose use is explicitly advocated only by IAP and AGA guidelines [7, 9]. The diagnostic accuracy of CE-EUS with or without fine needle aspiration (FNA) ranges from 40 to 96%, and its addition to abdominal imaging significantly increases overall diagnostic accuracy for PCNs [22, 23]. Furthermore, CE-EUS represent the gold standard in identifying mural nodules, helping to distinguish benign and malignant cysts [24–26]. The true advantage of EUS is to perform FNA of cyst fluid and to use it for cytological, biochemical, or DNA analysis. Analysis of CEA level using a cutoff of 192–200 ng/ml and cystic fluid amylase level proved to be useful in differentiating mucinous from non-mucinous PCNs [27]. A recent meta-analysis showed low pancreatic cyst fluid glucose level to have significantly improved diagnostic accuracy compared with CEA alone for the diagnosis of mucinous versus non mucinous PCNs [28]. Eventually, cytological examination is a highly specific test for the detection of malignancy with a specificity that approaches 100%, but this technique is hampered by the low cellularity of pancreatic cyst fluid and high heterogeneity of IPMNs. As a matter of fact, a single IPMN has multiple locules, and sample of one locule may not represent the entire lesion. Therefore, the sensitivity of cytopathology varies widely from 25 to 88% [2].
Indications for surgery: between evidence and guidelines

Most patients with pancreatic cancer are diagnosed at a late stage. Therefore, IPMNs with HGD, pancreatic intraepithelial neoplasia 3 (PanIN 3), and mucinous cystic neoplasia (MCN) with HGD represent a unique chance for a surgical cure as they are precursor lesions of pancreatic cancer [2, 29]. Whereas PanINs cannot be detected at traditional imaging, IPMNs and MCNs with HGD can be macroscopically identified and represent, according to the International Cancer of the Pancreas Screening Consortium, the ideal target for surgery to prevent pancreatic cancer [30]. Knowledge on biology and evolutionary path of IPMNs is increasing in recent years. Once a cyst becomes invasive, the estimated average window for its development from HGD is 3 years. These data by Noë et al. confirmed, once again, non-invasive IPMNs as potential origins of pancreatic cancer, providing opportunities for early detection and intervention [31].

Clinical and radiological parameters of guidelines

While waiting for more reliable predictor of malignancy, indications for surgery according to current consensus guidelines are still based on clinical and radiological parameters. MPD dilatation ≥ 10 mm, presence of enhancing mural nodule, jaundice, and malignant cytology have been historically recognized as risk factors for HGD and IC [2, 18, 32, 33]. Therefore, both the European and the IAP guidelines acknowledge them as indications for immediate surgery, namely, high-risk stigmata (HRS) and absolute indications (AIs) for surgery, respectively [7, 8].

Enhancing mural nodules are the strongest predictor of either HGD or IC for all types of suspected IPMNs [34]. Despite no evidence exists about a dimensional cutoff related to mural nodules, the risk of malignancy appears to be directly proportional to the size, and, according to guidelines, diameter ≥ 5 mm represents a clear indication for surgery [34].

While surgical series continue to identify MPD dilatation ≥ 10 mm, and even between 5 and 9 mm, as one of the best predictors of HGD and IC, reinforcing the policy of surgical resection, data on surveilled patients suggest that, in the absence of other features suspect for malignancy, MPD dilatation alone (above all between 5 and 9 mm) is characterized by a considerable risk of misdiagnosis and possible overtreatment [33, 35–37]. For this reason, it appears safe to suggest surveillance in asymptomatic patients who have “worrisome” MPD dilatation (5–9 mm) but lack other absolute or relative indications. In these cases, the risk of misdiagnosis with other pancreatic diseases is indeed relevant.

Cyst size has been historically recognized as a good indicator of malignancy risk. The IAP and European guidelines consider cyst size ≥ 3 cm and ≥ 4 cm, respectively, as a surgical indication. Of note, both these cutoffs were chosen arbitrarily. Cyst, as well as mural nodule, size, although not directly related to malignancy, might suggest for how long the cyst (or the mural nodule) has been growing and therefore give an esteem of the increase of the risk of malignancy. To provide a workaround, instead of cyst size alone, growth rate during follow-up might be considered a more accurate parameter when predicting the risk of progression, rather than cyst size alone at first observation [38].

In general, those listed as worrisome features (WFs) and relative indications (RIs) in the IAP and European guidelines, respectively, should not be considered strong stand-alone predictors of malignancy. Indeed, patients with WFs had a significantly better 5-year disease-specific survival compared with those with HRS (96% vs 60%, respectively) [35]. Of note, whereas in the European guidelines, one RI warrants surgical resection in patients without significant comorbidities, in the IAP guidelines, the presence of at least one WF warrants further diagnostic evaluation with EUS in order to better scale the risk of malignancy.

Both the IAP and the European guidelines differ from the AGA guidelines that recommend surgery in case of MPD ≥ 5 mm and presence of solid component, or cytology positive for malignancy [9]. Of note, the AGA guidelines suggests discontinuation of surveillance once the patient is no longer fit for surgery (as the other guidelines) or if there has been no change in the features of the cyst after 5 years, unlike any other guideline.

Dynamic predictors and indications for surgery beyond the guidelines

Guidelines policies have revealed their inaccuracy in predicting the risk of malignancy. The rate of LGD in surgical series applying such policies remains high (≥ 50%) with a peak of 77% in a recent multicentric snapshot study from US [18, 33, 36, 39]. Given the complication rate of pancreatic surgery, it does not seem acceptable that about half of the patients who undergo pancreatic resection for IPMN are overtreated or, at least, operated too soon. To supersede the inaccuracy of the above cited risk predictors of malignancy, the Verona group conducted an observational study focused on IPMNs “crossing-over” from observation to surgery to identify further dynamic predictors of malignant degeneration. They found that in BD-IPMNs under surveillance, development of additional WFs or HRS was associated with the presence of HGD, while harboring a stable WF carried the lowest risk of malignant disease [40]. Recently,
the Heidelberg group presented the largest surgical series on IPMNs ever published by a single referral center [41]. In this study, among 1439 patients, timing of resection was categorized according to final pathology: too early (LGD); too late (IC); and timely (intermediate and HGD). Only 34% and 88% of the “timely” and “too late” group had radiographic criteria of suspicion, respectively. Therefore, the authors advocated a cautious application of watch-and-wait policies. On the other side, large observation studies have recently identified subgroups of patients affected by BD-IPMNs with a low risk of malignant degeneration. Pergolini et al. found that small (<1.5 cm) BD-IPMNs without WFs have a significant lower risk of malignant degeneration compared to larger cysts [3], while the Verona group found that patients over 65 years of age with a “Trivial” cyst, defined as BD-IPMN not developing WFs or HRS in first 5 years of diagnosis, harbor the same risk of malignancy as the age-matched general population [38]. These data are consistent with those of Lee et al. that estimated an incidence of IC in patients with BD-IPMNs without significant changes within the first 5 years of surveillance around 1% and suggest that, when making surveillance decision of BD-IPMN beyond 5 years, the risk of malignant degeneration should be weighed against patients’ overall mortality risk [42].

Despite the inaccuracy of the existing tools, promising results are emerging from integrating cyst fluid genetics and clinical information. The application of an approach based on selected clinical features, imaging characteristics, and cyst fluid genetic and biochemical markers proved to be able to spare surgery in more than half of the patients who underwent resection of their cysts [43]. Hopefully, a combined approach including micro-RNAs and glycoproteins altered expression analysis and DNA testing of the pancreatic cyst fluid might be the key to better select the right candidates for surgery [43, 44].

**Eligibility of the patient and patient’s will**

In addition to clinical and radiographic indications, the surgical decision-making should be based on eligibility of the patient for surgery, namely, on age, life expectancy, frailty, overall health status, and comorbidities. Adequate counseling should be used to understand the patient’s will and motivation for surgery and, conversely, the psychological burden associated with a surveillance program. Indeed, patients under surveillance for presumed IPMN at low risk of malignancy may present the “Sword of Damocles” effect, namely, initial subclinical symptoms of somatization, depression, anxiety, sleep disorders, and a reduced perception of physical role functioning in comparison to patients who received surgery for the same condition [45]. A cautious approach is of uttermost importance to select only candidates with appropriate oncological targets (HGD or IC), physical condition, and adequate motivation for surgery, maximizing the benefits of surgical resection and avoiding the burden of unnecessary surgery.

Taking into account all these factors, the authors propose the algorithm displayed in Fig. 1 as the best current clinical management of patients diagnosed with an IPMN (Fig. 1).

**Surgery for IPMNs: intra- and postoperative implications**

Given the complexity of diagnostic work-up for IPMNs and the experience needed to assure a safe pancreatic resection and associated postoperative course or, looking at the flip side of the coin, a “safe” surveillance, patients with a suspected IPMNs should be always referred to high-volume center and discussed in a multidisciplinary meeting before undergoing resection (Fig. 1). As the goal of surgery is the prevention of pancreatic cancer or its treatment in the earliest stage, oncological major pancreatic resections with standard lymphadenectomy are the goal standard [46]. According to the pancreatic location, pancreaticoduodenectomy (PD), distal pancreatectomy (DP), or total pancreatectomy (TP) should be performed, either with an open or minimally invasive approach. Even if several centers have experience in this regard [47, 48], parenchyma sparing non-oncological procedures such as middle pancreatectomy or enucleation should be avoided or limited to very selected cases [7, 8].

PD is indicated for segmental dilatation of the MPD at the pancreatic head or suspected lesions of the head, uncinate process, or neck of the pancreas. In general, major morbidity, defined as Clavien-Dindo ≥ 3, and mortality rates for PD are around 20% and 3%, respectively [49]. DP with or without splenectomy is indicated for lesion of the body and tail of the pancreas. Major morbidity and mortality rates range from 14% up to 38% and from 0% up to 2% after minimally invasive DP (MIDP) and open DP (OPD), respectively [50, 51]. TP is indicated in cases of diffuse MPD involvement, multifocal disease in patients with family history positive for PDAC, and persistent HGD at the resection margin because the established risk for recurrence and/or cancer in these patients makes the morbidity of TP more acceptable [52]. Moreover, recent studies have reported improved perioperative outcomes and postoperative quality of life (QoL) after TP, presumably due to centralization at high-volume centers and development of long-acting insulin and modern pancreatic enzyme preparations [53–57].

**Intraoperative frozen section**

Intraoperative frozen section of the resection margin should always be performed during partial pancreatectomy in order to drive the extent of the resection [7, 8]. Whereas in case of
HGD or IC further resection up to TP is needed, in case of LGD should be avoided [58]. Worryingly, in a recent survey on the application of guidelines, 49% of responders believed that an additional resection was required in case of LGD at frozen section [59]. One challenging finding in frozen section is the presence of ducts with denuded epithelium, especially if the duct is dilatated. Indeed, the presence of a denuded epithelium has been associated with recurrence [60]. In this case, the need of further resection should be evaluated carefully, considering the characteristics of the resected lesion, the presence or absence of other lesions in the remaining pancreas, and the clinical condition of the patient [15].

**Recurrence and progression after pancreatic resection**

Resected invasive IPMNs recur in about half of the cases [61–65], while resected non-invasive IPMNs, namely, LGD or HGD, are associated with a risk of developing an IC in the pancreatic remnant around 2–3% [66–68]. Patients with resected non-invasive IPMNs have also a higher risk of developing additional features in the pancreatic remnant (e.g., development of a new cyst, increasing of MPD diameter, increasing of size of cysts in the pancreatic remnant) that is estimated around 20–25% [66–68]. Among all, increasing of MPD diameter after PD is the most challenging sign, given that in most cases it is a manifestation of a chronic obstructive pancreatitis rather than a sign of recurrence. These findings support the recommendation of the IAP and European guidelines that suggest lifelong follow-up regardless of tumor grade as long as the patients remains fit for surgery [7, 8]. Of note, the modality of follow-up after resection for IPMNs is not standardized and remains based on the experience of each center.

**Clonal heterogeneity and concomitant versus IPMN-derived pancreatic cancer**

IPMN with “concomitant” carcinoma has been defined as the presence of two lesions separated by an uninvolved segment of pancreatic parenchyma [14, 15, 69]. However, this definition needs to be implemented, as it recently emerged that a genetically independent IC (namely, a concomitant IC) could arise also in the contest of an IPMN, making it indistinguishable from an IPMN-derived IC by clinical and pathological features alone [70]. These findings are consistent with the recent identification of different tumorigenic pathways and independent polyclonal origins for IPMNs that are superseding the traditional idea of the adenoma-to-carcinoma sequence as the only model for progression of IPMNs [71, 72]. Indeed, Omori et al. described three different pathways of IPMN progression. These are the sequential type, where all driver mutations are shared by PDAC and co-occurring IPMNs; the branch-off type, where some driver mutations are shared by PDAC and co-occurring IPMNs; and de novo type, where PDAC has driver mutations not shared with co-occurring IPMNs [71]. These results support the hypothesis of “field cancerization,” in which the entire pancreas of some patients is at increased risk for PDAC [73].
and underlie, once again, how IPMNs are not an obligate precursor of PDAC. With this in mind, not only traditional clinical-radiological features appear unable to accurately predict the risk of malignancy, but also the most promising cyst fluid analysis, in case of PDAC adjacent to an IPMN, but genetically independent, would likely fail to identify mutations from high risk lesion, as the monitored cyst fluid would not contain any high-risk mutant DNA molecules of PDAC [70].

Of note, despite the huge clinical relevance that the understanding of the biology of IPMNs might have, a recent survey on the application of guidelines found that only 56% of responders usually distinguished between IPMN-derived IC and a concomitant PDAC [59].

Open controversies

Although high quality evidence identifies HGD as the right and timely target for resection, the reality is much more complex. Many controversies and pitfalls still exist regarding surgical treatment of IPMNs:

1. IPMNs are genetically heterogeneous. Therefore, pre-operative FNA or biopsy is usually not representative of the entire lesion. Moreover, not all low-grade lesions will progress to HGD and, eventually, to IC in an entire lifetime [71, 72].
2. IPMNs are often multifocal, and even unifocal non-invasive IPMNs are related to an increased risk of harboring malignancy in the pancreatic remnant [73]. Only TP can eliminate the risk of malignant progression, while partial pancreatectomies are inevitably related with an increased risk of progression, potentially even after resection of non-invasive IPMNs [66–68]. However, due to long-term postoperative outcomes, TP cannot be advocated for all IPMNs even for multifocal forms.
3. Radiological features, tumor markers, and clinical signs at present have proved to be inaccurate in predicting the risk of malignancy, setting the ground for the perception of surgical resection as the “best” treatment for IPMNs [41]. However, surveillance remains the option of choice for most IPMNs as the vast majority of “trivial” lesions will never progress [38]. Future research efforts should keep focusing on the right target for surveillance and even more on surveillance discontinuation.
4. Although combined approaches including DNA testing of the pancreatic cyst fluid are showing promising results in predicting the occurrence of IPMN-derived carcinomas, these cannot be effective in predicting the risk of a concomitant PDAC, both distant or adjacent to the IPMN [70].

Conclusion

In conclusion, where and when to resect an IPMN remain a matter of debate. While waiting for more reliable tools, multidisciplinary team discussion, guidelines, and a patient-centered decision-making process should guide the treatment. The suggested clinical management of IPMN can be summarized as follows (Fig. 1). If no absolute nor relative indications for surgery are present at first visit or no modifications of the cyst appears over time, surveillance should be undertaken and proceeded, respectively. If relative indications are present at first visit or appears and/or growth rate is ≥ 2.5 mm/year over time, further diagnostic work-up with EUS-FNA should be performed. If absolute indications are present at first visit or appears over time, the patient should be advised for surgery. Every step of the clinical management should be discussed with the patient and confirmation factors as age and life expectancy, frailty, overall health status, comorbidities, patient’s will, and motivation must be evaluated. Once the patient is considered unfit for surgery for any reason, no further surveillance is required.

Authors’ contributions Study conception and design: not applicable.
Acquisition of data: not applicable.
Analysis and interpretation of data: not applicable.
Drafting of manuscript: Anna Burelli, Giampaolo Perri.
Critical revision of manuscript: Roberto Salvia, Giovanni Marchegiani.

Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

Data availability Not applicable.

Code availability Not applicable.

Declarations

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declarations and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source.
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Zerboni G, Signoretto M, Crippa S, Falconi M, Arcidiacono PG, Capurso G (2019) Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology 19(1):2–9. https://doi.org/10.1016/j.pan.2018.11.014

2. Singh AD, Kosay EJ, Chari ST, Maitra A (2019) Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 156(7):2024–2040. https://doi.org/10.1053/j.gastro.2019.01.259

3. Pergolini I, Sahora K, Ferrone CR, Morales-Oyarvide V, Wolpin BM, Mucci LA, Brugge WR, Mino-Kenudson M, Patino M, Sahani DV et al (2017) Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology 153(5):1284–1294.e1. https://doi.org/10.1053/j.gastro.2017.07.019

4. Lawrence SA, Attiyeh MA, Seier K, Gönen M, Schattner M, Haviland DL, Balachandran VP, Kingham TP, D’Angelica MI, DeMatteo RP et al (2017) Should patients with cystic lesions of the pancreas undergo long-term radiographic surveillance?: Results of 3024 patients evaluated at a single institution. Ann Surg 266(3):536–544. https://doi.org/10.1097/SLA.000000000002371

5. Han Y, Lee H, Kang JS, Kim JR, Kim HS, Lee JM, Lee K-B, Kwon W, Kim S-W, Gang J-Y (2018) Progression of pancreatic branch duct intraductal papillary mucinous neoplasm associated with cyst size. Gastroenterology 154(3):576–584. https://doi.org/10.1053/j.gastro.2017.10.013

6. Balduzzi A, Marchegiani G, Pollini T, Biancotto M, Caravita A, Stigliani E, Burelli A, Bassi C, Salvia R (2021) Systematic review and meta-analysis of observational studies on BD-IPMNs progression to malignancy. Pancreatology S1424–3903(21):00148–00154. https://doi.org/10.1016/j.pan.2021.04.009

7. Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL (2017) Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 17(5):738–753. https://doi.org/10.1016/j.pan.2017.07.007

8. European Study Group on Cystic Tumours of the Pancreas (2018) European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67(5):789–804. https://doi.org/10.1136/gutjnl-2018-316027

9. Vege SS, Ziring B, Jain R, Moayyed P, Clinical Guidelines Committee; American Gastroenterology Association (2015) American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 148(4):819–822. https://doi.org/10.1053/j.gastro.2015.01.015 (quiz12–13)

10. Sahora K, Fernández-del Castillo C (2015) Intraductal papillary mucinous neoplasms. Curr Opin Gastroenterol 31(5):424–429. https://doi.org/10.1097/MOG.0000000000000198

11. Oyama H, Tada M, Takagi K, Tateishi K, Hamada T, Nakai Y, Hakuta R, Ijichi H, Ishigaki K, Kanai S et al (2020) Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology 158(1):226–237.e5. https://doi.org/10.1053/j.gastro.2019.08.032

12. Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Ferrone CR, Sahani D, Pitman MB, Warshaw AL, Lillemoe KD, Fernandez-del Castillo CF (2013) Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 258(3):466–475. https://doi.org/10.1097/SLA.00000000000018048

13. Sahora K, Fernández-del Castillo C, Dong F, Marchegiani G, Thayer SP, Ferrone CR, Sahani DV, Brugge WR, Warshaw AL, Lillemoe KD et al (2014) Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery 156(3):611–621. https://doi.org/10.1016/j.surg.2014.04.023

14. Basturk O, Hong S-M, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Bovers LAA, Fukushima N, Goggins M, Hruban RH et al (2015) A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39(12):1730–1741. https://doi.org/10.1097/PAS.0000000000000533

15. Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, Bassi C, Salvia R, Malleo G, Paella S et al (2016) Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreaticobiliary tract: recommendations of Verona consensus meeting. Ann Surg 263(1):162–177. https://doi.org/10.1097/SLA.000000000001173

16. Castillo CF, Adsay NV (2010) Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 139(3):708–713.e2. https://doi.org/10.1053/j.gastro.2010.07.025

17. Marchegiani G, Andrianello S, Mattelol C, Pollini T, Secchettin E, Tedesco G, D’Onofrio M, Malleo G, Bassi C, Salvia R (2019) The actual prevalence of symptoms in pancreatic cystic neoplasms: a prospective propensity matched cohort analysis. Dig Surg 36(6):522–529. https://doi.org/10.1159/000495039

18. Attiyeh M, Castillo CF, Efishtat MA, Eaton A, Gönen M, Batts R, Pergolini I, Rezaee N, Lillemoe K, Ferrone C et al (2018) Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the pancreatic surgery consortium. Ann Surg 267(1):157–163. https://doi.org/10.1097/SLA.0000000000002015

19. Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, Sandrasagar K, Akisik F, Howard TJ, Nakeeb A et al (2008) CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 12(1):101–109. https://doi.org/10.1007/s11605-007-0367-9

20. Salvia R, Malleo G, Marchegiani G, Pennacchio S, Piaelli S, Paini M, Pea A, Butturini G, Pedetolle P, Bassi C (2012) Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery 152(3, Supplement):S135–S142.

21. Jones MJ, Buchanan AS, Neal CP, Dennison AR, Metcalfe MS, Garcea G (2013) Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology 13(4):436–442. https://doi.org/10.1016/j.pan.2013.05.007

22. ASGE Standards of Practice Committee, Muthusamy VR, Chandrasekhar V, Acosta RD, Bruining DH, Chathadi KV, Eloubeidi MA, Faulx AL, Fonkalresed L, Gurudu SR et al (2016) The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms. Gastrointest Endosc 84(1):1–9. https://doi.org/10.1016/j.gie.2016.04.014

23. Khoshab MA, Kim K, Lennon AM, Shin EJ, Tignor AS, Ama-teau SK, Singh VK, Wolfgang CL, Hruban RH, Canto MI (2013) Should we do EUS/FNA on patients with pancreatic cysts? The
incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas 42(4):717–721. https://doi.org/10.1097/MPA.0b013e3182883a91

24. Zhong N, Zhang L, Takahashi N, Shalmiyev V, Canto MI, Jain JE, Deutsch JC, DeWitt J, Eloubeidi MA, Gleeson FC et al (2012) Histologic and imaging features of mural nodules in mucinous pancreatic cysts. Clin Gastroenterol Hepatol 10(2):192–198. https://doi.org/10.1016/j.cgh.2011.09.029 (198.e1–2)

25. Harima H, Kaino S, Shinoda S, Kawano M, Suenaga S, Sakaida I (2015) Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol 21(20):6252–6260. https://doi.org/10.3748/wjg.v21.i20.6252

26. Lisotti A, Napolone B, Facciornusso A, Cominardi A, Crinò SF, Brighi N, Gincul R, Kitano M, Yamashita Y, Marchegiani G et al (2021) Contrast-enhanced EUS for the characterization of mural nodules within pancreatic cystic neoplasms: systematic review and meta-analysis. Gastrointest Endosc S0016-5107(21):01475–0000378

27. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlow T, Regan S, del Castillo CF, Warshaw AL (2004) Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 126(5):1330–1336. https://doi.org/10.1053/j.gastro.2004.02.013

28. McCarty TR, Garg R, Rustagi T (2021) Pancreatic cyst fluid glucose in differentiating mucinous from nonmucinous pancreatic cysts: a systematic review and meta-analysis. Gastrointest Endosc. https://doi.org/10.1016/j.gi.2021.04.025

29. Iacobuzzi-Donahue CA (2012) Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 61(7):1085–1094. https://doi.org/10.1136/gut.2010.236026

30. Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK et al (2020) Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69(1):7–17. https://doi.org/10.1136/gutjnl-2019-319352

31. Noé M, Niknafs N, Fischer CG, Hackgeng WM, Beleva Guthrie V, Hosoda W, Debjak M, Papp E, Adleff V, White JR et al (2020) Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun 11(1):4085. https://doi.org/10.1038/s41467-020-17917-8

32. Jang J-Y, Kim S-W, Ahn YJ, Yoon Y-S, Choi MG, Lee KU, Han JK, Kim WH, Lee YJ, Kim SC et al (2005) Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol 12(2):124–132. https://doi.org/10.1245/ASO.2005.02.030

33. Del Chiaro M, Beckman R, Ateeb Z, Orsini N, Rezaee N, Manos L, Valente R, Yuan C, Ding D, Margonis GA et al (2020) Main duct dilatation is the best predictor of high-grade dysplasia or tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol 12(2):124–132. https://doi.org/10.1245/s10434-018-6425-6

34. Marchegiani G, Andrianello S, Pollini T, Caravati A, Biancotto M, Scuccettin E, Bonamini D, Mallego C, Bassi C, Salvia R (2019) “Trivial” cysts redefine the risk of cancer in presumed branch-duct intraductal papillary mucinous neoplasms of the pancreas: a potential target for follow-up discontinuation? Am J Gastroenterol 114(10):1678–1684. https://doi.org/10.14309/ajg.000000000000378

35. Khoury RE, Cabrè C, Maker VK, Banulescu M, Wasserman M, Maker AV (2018) What is the incidence of malignancy in resected intraductal papillary mucinous neoplasms? An analysis of over 100 US institutions in a single year. Ann Surg Oncol 25(6):1746–1751. https://doi.org/10.1245/s10434-018-6425-6

36. Marchegiani G, Pollini T, Andrianello S, Tomasoni G, Biancotto M, Javed AA, Kinney-Küster B, Amini N, Han Y, Kim H et al (2021) Progression vs cyst stability of branch-duct intraductal papillary mucinous neoplasms after observation and surgery. JAMA Surg. https://doi.org/10.1001/jamasurg.2021.1802

37. Tjaden C, Sandini M, Mihaljevic AL, Kaiser J, Khristenko E, Mayer P, Hinz U, Gaida MM, Berchtold C, Diener MK et al (2021) Risk of the watch-and-wait concept in surgical treatment of intraductal papillary mucinous neoplasm. JAMA Surg. https://doi.org/10.1001/jamasurg.2021.0950

38. Lee BS, Nguyen AK, Tekeste TF, Chang K, Girgis A, Adeyemo M, Hanna MS, Yao JF, Kwok KK, Giap AQ et al (2021) Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with no change in first 5 years of diagnosis. Pancreatology 21(1):144–154. https://doi.org/10.1016/j.pan.2020.10.040

39. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ et al (2019) A multimodality test to guide the management of patients with a pancreatic cyst. Sci Transl Med 11(501):eaav4772. https://doi.org/10.1126/scitranslmed.aav4772

40. Maker AV, Carrara S, Jamieson NB, Pelay-Luna M, Lennon AM, Dal Molin M, Scarp a A, Frulloni L, Brugge WR (2015) Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg 220(2):243–253. https://doi.org/10.1016/j.jamcollsurg.2014.11.001

41. Marinielli V, Scuccettin E, Andrianello S, Moretti C, Donvito S, Marchegiani G, Esposito A, Casetti L, Salvia R (2020) Psychological distress in patients under surveillance for intraductal papillary mucinous neoplasms of the pancreas: the “Sword of Damocles” effect calls for an integrated medical and psychological approach a prospective analysis. Pancreatology 20(3):505–510. https://doi.org/10.1016/j.pan.2020.01.006

42. Pollini T, Andrianello S, Caravati A, Perri G, Mallego G, Paella S, Marchegiani G, Salvia R (2019) The management of intraductal papillary mucinous neoplasms of the pancreas. Minerva Chir 74(5):414–421. https://doi.org/10.23736/S0026-4733.19.01845-8

43. Bassi C (2007) Middle segment pancreatic resection: a useful tool in the management of pancreatic neoplasms. J Gastrointest Surg 11(6):726–729. https://doi.org/10.1016/j.jvenl.007-0179-y
48. Kaiser J, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O, Schneider L, Büchler MW, Hackert T (2017) Enucleation: a treatment alternative for branch duct intraductal papillary mucinous neoplasms. Surgery 161(3):602–610. https://doi.org/10.1016/j.surg.2016.09.026

49. Bassi C, Marchegiani G, Giuliani T, Di Gioia A, Andrianello S, Zingaretti CC, Brentegani G, De Pastena M, Fontana M, Pea A et al (2021) Pancreatoduodenectomy at the Verona Pancreas Institute: the evolution of indications, surgical technique and outcomes: a retrospective analysis of 3000 consecutive cases. Ann Surg. https://doi.org/10.1097/SLA.0000000000004753

50. de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkstra M et al (2019) Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg 269(1):2–9. https://doi.org/10.1097/SLA.0000000000002979

51. Björnsson B, Larsson AL, Hjalmarsson C, Gasslander T, Sandström P (2020) Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy: randomized controlled trial. Br J Surg 107(10):1281–1288. https://doi.org/10.1002/bjs.11554

52. Griffin JF, Poruk KE, Wolfgang CL (2016) Is it time to expand the role of total pancreatectomy for IPMN? Dig Surg 33(4):335–342. https://doi.org/10.1097/01.dss.00004945019

53. Pulvirenti A, Pea A, Rezaee N, Gasparini C, Malleo G, Weiss MJ, Cameron JL, Wolfgang CL, He J, Salvia R (2019) Perioperative outcomes and long-term quality of life after total pancreatectomy. BJIS (British Journal of Surgery) 106(13):1819–1828. https://doi.org/10.1002/bjs.11185

54. Stoop TF, Ateeb Z, Ghorbani P, Scholten L, Arnelo U, Besslink MG, Del Chiaro M (2020) Impact of endocrine and exocrine insufficiency on quality of life after total pancreatectomy. Ann Surg Oncol 27(2):587–596. https://doi.org/10.1007/s10434-019-07853-3

55. Stoop TF, Ateeb Z, Ghorbani P, Scholten L, Arnelo U, Besslink MG, Del Chiaro M (2020) Surgical outcomes after total pancreatectomy: a high-volume center experience. Ann Surg Oncol. https://doi.org/10.1007/s10434-020-08957-x

56. Scholten L, Latenstein AEJ, van Eijck C, Erdmann J, van der Harst E, Mieog JS, Molenaar IQ, van Santvoort HC, De Vries JH, Besslink MG et al (2019) Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. Surgery 166(6):1017–1026. https://doi.org/10.1016/j.surg.2019.07.025

57. Marchegiani G, Perri G, Burelli A, Zoccattelli F, Andrianello S, Luchini C, Donadello K, Bassi C, Salvia R (2021) High-risk pancreatic anastomosis vs. Total pancreatectomy after pancreatoduodenectomy: postoperative outcomes and quality of life analysis. Ann Surg. https://doi.org/10.1097/SLA.0000000000004840

58. Nara S, Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiroaka N (2009) Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? J Am Coll Surg 209(5):614–621. https://doi.org/10.1016/j.jamcollsurg.2009.07.023

59. Marchegiani G, Salvia R, Verona EBM 2020 on IPMN (2021) Guidelines on pancreatic cystic neoplasms: major inconsistencies with available evidence and clinical practice-results from an international survey. Gastroenterology 160(7):2234–2238. https://doi.org/10.1053/j.gastro.2021.02.026

60. Falconi M, Salvia R, Bassi C, Zamboni G, Talamini G, Pedezzoli P (2001) Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg 88(3):376–381. https://doi.org/10.1046/j.1365-2168.2001.01720.x

61. Park J, Lee KT, Jang TH, Seo YW, Lee KH, Lee JK, Jang K-T, Heo JS, Choi SH, Choi DW et al (2011) Risk factors associated with the postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 40(1):46–51. https://doi.org/10.1097/MPA.0b013e3181f66b74

62. Passot G, Lebeau R, Hervieu V, Ponchon T, Pilleul F, Adham M (2012) Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors. Pancreas 41(1):137–141. https://doi.org/10.1097/MPA.0b013e318222bc9c

63. Kang MJ, Jang J-Y, Lee KB, Chang YR, Kwon W, Kim S-W (2014) Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 260(2):356–363. https://doi.org/10.1097/SLA.0000000000004740

64. Marchegiani G, Mino-Kenudson M, Ferrone CR, Morales-Oyarvide V, Warshaw AL, Lillehoe KD, Castillo CF-D (2015) Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg 262(6):1108–1114. https://doi.org/10.1097/SLA.0000000000001008

65. Hirono S, Shimizu Y, Ohtsuka T, Kin T, Hara K, Kanno A, Koshita S, Hanada K, Kitano M, Inoue H et al (2020) Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol Hepatol 35(1):86–99. https://doi.org/10.1111/jgh.14772

66. Miller JR, Meyer JE, Waters JA, Al-Haddad M, Dewitt J, Sherman S, Lillehoe KD, Schmidt CM (2011) Outcome of the pancreateic remnant following segmental pancreatectectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) 13(11):759–766. https://doi.org/10.1111/j.1477-2578.2011.00354.x

67. Al Efishat M, Atiyeh MA, Eaton AA, Gönen M, Basturk O, Klimstra D, D’Angelica MI, DeMatteo RP, Kingdom TP, Balachandran V et al (2018) Progression patterns in the remnant ancreas after resection of non-invasive or micro-invasive intraductal papillary mucinous neoplasms (IPMN). Ann Surg 256(6):1752–1759. https://doi.org/10.1097/SLA.0000000000004645

68. Amini N, Habib JR, Blair A, Rezaee N, Kimy-Köster B, Cameron JL, Hurban RH, Weiss MJ, Fishman EK, Laffaro KJ et al (2020) Invasive and non-invasive progression after resection of non-invasive intraductal papillary mucinous neoplasms. Ann Surg. https://doi.org/10.1097/SLA.0000000000004488

69. Yamaguchi K, Kanemitsu S, Hatori T, Maguchi H, Shimizu Y, Tada M, Nakagohri T, Hanada K, Osanai M, Noda Y et al (2011) Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40(4):571–580. https://doi.org/10.1097/MPA.0b013e318215010c

70. Felsenstein M, Noé M, Masica DL, Hosoda W, Chianchiano P, Fischer CG, Lionheart G, Boverssen LAA, Pea A, Yu J et al (2018) IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut 67(9):1652–1662. https://doi.org/10.1136/gutjnl-2017-315062

71. Omori Y, Ono Y, Tanino M, Karasaki H, Yamaguchi H, Furukawa T, Enomoto K, Ueda J, Sumi A, Katayama J et al (2019) Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features. Gastroenterology 156(3):647–661.e2. https://doi.org/10.1053/j.gastro.2018.10.029

72. Fischer CG, Beleva Guthrie V, Braxton AM, Zheng L, Wang P, Song Q, Griffin JF, Chianchiano PE, Hosoda W, Niknafs N et al (2019) Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations.
Remotti HE, Winner M, Saif MW (2012) Intraductal papillary mucinous neoplasms of the pancreas: clinical surveillance and malignant progression, multifocality and implications of a Field-Defect. JOP 13(2):135–138

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.